FARXIGA (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the FARXIGA drug offered from AstraZeneca Pharmaceuticals LP. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
| NON-PROPRIETARY NAME: | DAPAGLIFLOZIN |
| SUBSTANCE NAME: | DAPAGLIFLOZIN PROPANEDIOL |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2008-01-14 |
| END MARKETING DATE: | 0000-00-00 |
FARXIGA HUMAN PRESCRIPTION DRUG Details:
| Item Description | FARXIGA from AstraZeneca Pharmaceuticals LP |
| LABELER NAME: | AstraZeneca Pharmaceuticals LP |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 5(mg/1) |
| START MARKETING DATE: | 2008-01-14 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0310-6205_0dbbd015-9be3-4ea9-86d9-1cc6c79521d3 |
| PRODUCT NDC: | 0310-6205 |
| APPLICATION NUMBER: | NDA202293 |
Other DAPAGLIFLOZIN PROPANEDIOL Pharmaceutical Manufacturers / Labelers:
